Overview
Study Evaluating Mitoxantrone in Multiple Sclerosis
Status:
Terminated
Terminated
Trial end date:
1969-12-31
1969-12-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of PfizerTreatments:
Mitoxantrone
Criteria
Inclusion Criteria:- Secondary progressive MS in an active stage
- EDSS between 3 and 6
Exclusion Criteria:
- Benign or primary progressive MS
- Patients with cardiac risk factors
- Patients who have already received mitoxantrone